费布里病:对病理生理学的洞察力和新的治疗策略
Sophie Elizabeth Thompson1,2, Ashwin Roy1,2, Tarekegn Geberhiwot3,4
1Department of Cardiovascular Sciences, School of Medical Sciences, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK.
Biomedicines
|March 28, 2025
概括
费布里病 (FD) 需要除了酶替代疗法 (ERT) 和口服陪伴疗法 (OCT) 外的新疗法. 新兴的辅助疗法在治疗FD方面表现有前途.
科学领域:
- 遗传学和罕见疾病.
- 代谢障碍 代谢障碍 代谢障碍
- 溶酶体储存障碍 溶酶体储存障碍
背景情况:
- 费布里病 (FD) 是由α-galactosidase A (alpha-GalA) 缺乏引起的X关联疾病,导致葡萄糖脂积累和器官损伤.
- 目前的治疗方法,如酶替代疗法 (ERT) 和口服护理疗法 (OCT),有效性有限,特别是在晚期.
- 病理生理学涉及慢性炎症和线粒体,溶酶体和内皮功能障碍.
研究的目的:
- 审查目前法布里病治疗方法的局限性.
- 探索针对FD新途径的辅助疗法的潜力.
- 倡导扩大治疗策略和定制研究.
主要方法:
- 关于法布里病病理生理学和治疗的当前文献的叙事综述.
- 对辅助疗法 (SGLT2 抑制剂,GLP-1 激动剂,MRA) 和它们的机制进行分析.
- 讨论FD的理论益处和临床试验的需要.
主要成果:
- 辅助疗法调节涉及FD的关键途径,包括自,氧化应激和炎症.
- 这些疗法在其他疾病中已经证明了心血管和的益处.
- 对于它们在法布里病中的实用性存在理论基础,但专门的试验正在等待.
结论:
- 扩大治疗策略超越ERT和OCT对于改善FD结果至关重要.
- 基于证据的辅助治疗提供了一个有前途的多方面的方法.
- 需要进一步的研究来确认各种FD表型的疗效,包括女性和非经典变体.
相关概念视频
Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Introduction to Fibroblasts
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
Cystic Fibrosis: Pathogenesis
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


